Ligation of OX40 provides costimulation to activated T cells, increasing their survival and prolonging responses.49 Studies have observed Treg OX40 ligation to promote accumulation of quiescent Tregs and antagonise FOXP3 induction in naïve CD4+ T cells.49 Therefore, therapeutically targeting the OX40 axis to stimulate long‐term T‐cell responses and reduce Treg burden is an attractive target for treatment of lung cancers. This evidence concerns the gene TNFRSF4 and lung carcinoma.